Correlation of MRI characteristics with KRAS mutation status in pancreatic ductal adenocarcinoma
Abdominal Radiology · 2025
DOI: 10.1007/s00261-025-04888-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Abdominal Radiology, 2025. Verfasst von Junjian Shen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Magnetic Resonance Imaging, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Science and Technology Innovation Action Plan" Star Cultivation (Sailing Program), the China Postdoctoral Science Foundation, Shanghai Municipal Health Commission Health Industry Clinical Research Special Program (Youth Project).
Abstract (Originalsprache)
PURPOSE: To investigate MRI features associated with KRAS mutation status in PDAC and their clinical implications. MATERIALS AND METHODS: In our study, 1474 patients pathologically confirmed PDAC patients between January 2016 and December 2023 were evaluated. Patients with genetic testing (KRAS mutation status) and MRI examination were enrolled and grouped as KRAS-mutated PDAC and non-KRAS-mutated PDAC. Contrast-enhanced MRI features, clinicopathologic findings, and prognosis were compared between two groups. RESULTS: A total of 308 surgically confirmed PDAC patients (median age, 67 years [IQR, 59, 72]; 183 male and 125 female) with genetic testing data were included, of which 258 had KRAS-mutated PDAC and 50 had non-KRAS-mutated PDAC. KRAS-mutated PDAC demonstrated distinct clinicopathological characteristics, including higher rates of diabetes (OR, 2.450, 95% CI, 1.151-5.212, P = 0.020), pathological peripheral nerve infiltration (OR, 2.296, 95% CI, 1.083-4.867, P = 0.030), and pN stage (OR, 2.006, 95% CI, 1.012-3.976, P = 0.046). The 1-, 3-, 5-year OS rate was worse for KRAS-mutated PDAC (89.9%, 45.4%, 23.2% vs. 95.1%, 60.4% 60.4%, P = 0.045). Rim enhancement (OR = 2.039, 95% CI: 1.053, 3.951, P = 0.035) and larger tumor size (OR = 3.286, 95% CI: 1.523, 7.089, P = 0.002) were identified as distinctive MRI features for KRAS-mutated PDAC. CONCLUSION: KRAS-mutated PDAC presents unique clinical and pathological features and is associated with poorer prognosis. Rim enhancement and larger tumor size on MRI were identified as features associated with KRAS-mutated PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
- , Department of Pathology, Zhongshan Hospital, Fudan University, PR China.
- , Department of Interventional Radiology, Zhongshan Hospital, Fudan university, PR China.
- Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. sht1720@163.com.
- Department of Radiology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, PR China.
Förderung
- Science and Technology Innovation Action Plan" Star Cultivation (Sailing Program)
- the China Postdoctoral Science Foundation
- Shanghai Municipal Health Commission Health Industry Clinical Research Special Program (Youth Project)
- Science and Technology Innovation Action Plan” Star Cultivation
Zitieren
APA
Shen, J., Wang, X., Yu, K., Liu, K., Wang, X., Sun, H., Zhou, J., & Zeng, M. (2025). Correlation of MRI characteristics with KRAS mutation status in pancreatic ductal adenocarcinoma. Abdominal Radiology. https://doi.org/10.1007/s00261-025-04888-x
Vancouver
Shen J, Wang X, Yu K, Liu K, Wang X, Sun H, et al. Correlation of MRI characteristics with KRAS mutation status in pancreatic ductal adenocarcinoma. Abdominal Radiology. 2025. doi:10.1007/s00261-025-04888-x
BibTeX
@article{Shen2025,
author = {Shen, Junjian and Wang, Xingxing and Yu, Keqin and Liu, Kai and Wang, Xiaolin and Sun, Haitao and Zhou, Jianjun and Zeng, Mengsu},
title = {Correlation of MRI characteristics with KRAS mutation status in pancreatic ductal adenocarcinoma},
journal = {Abdominal Radiology},
year = {2025},
doi = {10.1007/s00261-025-04888-x}
}
EUVIMED